| 前收市價 | 5.27 |
| 開市 | 5.24 |
| 買盤 | 5.11 x 100 |
| 賣出價 | 5.18 x 200 |
| 今日波幅 | 5.15 - 5.24 |
| 52 週波幅 | 4.87 - 13.49 |
| 成交量 | |
| 平均成交量 | 110,911 |
| 市值 | 1.825B |
| Beta 值 (5 年，每月) | 1.17 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.25 |
| 業績公佈日 | 2024年5月22日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 12.80 |
InvestorPlace3 Growth Stocks to Buy at 52-Week Lows
Growth stocks have been huge winners over the past 18 months. Investors have shrugged off the sector’s 2022 bust and returned to growth and technology names with great enthusiasm. This move makes sense. The Federal Reserve’s planned rate cuts for later this year could be a major catalyst for the growth names in particular. And the rapid increase in activity in fields such as artificial intelligence and semiconductors has been a strong tailwind as well. However, not all growth stocks have taken p
Insider MonkeyEvotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript
Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript April 24, 2024 Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333. Evotec SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, welcome to […]
BenzingaLife Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast
European life science company Evotec SE (NASDAQ:EVO) announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. The company is focusing on and rightsizing organizations to overcome the challenging market environment and return to sustainable and profitable growth. Shared R&D and Just–Evotec Biologics will replace EVT Execute & EVT Innovate segments in a streamlined reporting structure as of Q1 2024. The priority reset is
